Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
Introduction and objective Multiple myeloma (MM) is an incurable condition with variable clinical course. The study included a group of patients with especially poor-prognosis, individuals with relapsed/refractory multiple myeloma (RRMM) and specific cytogenetic disorders. Among the currently used t...
Main Authors: | Aneta Szudy-Szczyrek, Sylwia Chocholska, Oliwia Bachanek-Mitura, Olga Czabak, Radosław Mlak, Michał Szczyrek, Justyna Muzyka-Kasietczuk, Marek Hus |
---|---|
Format: | Article |
Language: | English |
Published: |
Institute of Rural Health
2021-06-01
|
Series: | Annals of Agricultural and Environmental Medicine |
Subjects: | |
Online Access: | http://www.aaem.pl/Efficacy-of-ixazomib-lenalidomide-dexamethasone-in-high-molecular-risk-relapsed-refractory,137788,0,2.html |
Similar Items
-
A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
by: Anna Furlan, et al.
Published: (2024-04-01) -
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
by: Maral DerSarkissian, et al.
Published: (2023-12-01) -
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01) -
Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01) -
Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Multiple Myeloma Patient Following Therapy with Ixazomib-Lenalidomide-Dexamethasone
by: Catalin Constantinescu, et al.
Published: (2022-04-01)